OIS at AAO 2015

Allegro Ophthalmics, LLC

Nov 12, 2015 10:45am ‐ Nov 12, 2015 10:53am


Description

Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Currently in multiple Phase 2 studies, Allegro’s Luminate has the potential to provide new treatment options for patients with diabetic macular edema, non-proliferative diabetic retinopathy, neovascular age-related macular degeneration and vitreomacular traction.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content